Neratinib received FDA approval in 2017 for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed breast cancer, following adjuvant therapy. The approval was based on clinical trial data demonstrating its efficacy in reducing the risk of invasive breast cancer recurrence or death. [1]
What is Neratinib's approved use?
Neratinib is approved for the extended adjuvant treatment of early-stage HER2-positive breast cancer. This means it is used after initial treatment, such as surgery and chemotherapy, to lower the chance of the cancer returning. The drug is indicated for patients who have already completed prior adjuvant therapy. [1]
How effective is Neratinib?
In clinical trials, neratinib showed a statistically significant reduction in the risk of invasive disease recurrence or death compared to placebo in patients with early-stage HER2-positive breast cancer. [1]
What are the main side effects of Neratinib?
The most common side effects reported with neratinib include diarrhea, nausea, vomiting, abdominal pain, fatigue, rash, stomatitis, and decreased appetite. Diarrhea is a significant side effect that requires careful management. [1]
When does Neratinib's patent expire?
Information on specific patent expiry dates for Neratinib can be found on DrugPatentWatch.com. These patents are crucial for understanding when generic versions of the drug might become available. [2]
Are there alternatives to Neratinib for HER2-positive breast cancer?
Other HER2-targeted therapies are available for breast cancer treatment, depending on the stage and specific characteristics of the disease. These may include trastuzumab, pertuzumab, and ado-trastuzumab emtansine. The choice of treatment is individualized based on patient factors and clinical guidelines.
What is the regulatory status of Neratinib?
Neratinib has received approval from the U.S. Food and Drug Administration (FDA) and other regulatory bodies in different regions for its specified indication. [1]